1h Free Analyst Time
Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.Speak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.Shionogi & Co Ltd Key Recent Developments
Nov 21, 2022: SHIONOGI Integrated Report 2022 won silver award in the WICI Japan Integrated Report Award 2022Oct 31, 2022: Shionogi announces 1st Half of Fiscal 2022 Financial Results
Oct 17, 2022: Shionogi and Hirakata City, Osaka sign partnership agreement for support and awareness-raising of infectious disease control
Oct 04, 2022: Shionogi and MPP enter Covid-19 antiviral licencing deal
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company- Shionogi & Co Ltd - Key Facts
- Shionogi & Co Ltd - Key Employees
- Shionogi & Co Ltd - Key Employee Biographies
- Shionogi & Co Ltd - Major Products and Services
- Shionogi & Co Ltd - History
- Shionogi & Co Ltd - Company Statement
- Shionogi & Co Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Joint Venture
- Company Overview
- Shionogi & Co Ltd - Business Description
- R&D Overview
- Shionogi & Co Ltd - Corporate Strategy
- Shionogi & Co Ltd - SWOT Analysis
- SWOT Analysis - Overview
- Shionogi & Co Ltd - Strengths
- Shionogi & Co Ltd - Weaknesses
- Shionogi & Co Ltd - Opportunities
- Shionogi & Co Ltd - Threats
- Shionogi & Co Ltd - Key Competitors
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
- Shionogi & Co Ltd, Recent Deals Summary
- Nov 21, 2022: SHIONOGI Integrated Report 2022 won silver award in the WICI Japan Integrated Report Award 2022
- Oct 31, 2022: Shionogi announces 1st Half of Fiscal 2022 Financial Results
- Oct 17, 2022: Shionogi and Hirakata City, Osaka sign partnership agreement for support and awareness-raising of infectious disease control
- Oct 04, 2022: Shionogi and MPP enter Covid-19 antiviral licencing deal
- Aug 29, 2022: Shionogi Continuously selected for inclusion in all ESG Indices Adopted by the Government Pension Investment Fund (GPIF)
- Jul 01, 2022: Notice regarding the launch of the new SHIONOGI Group Brand
- May 23, 2022: Shionogi announces appointment of Corporate officers, Corporate Reorganization and Personnel Reassignment
- Apr 05, 2022: Shionogi partners with Cloudera to accelerate R&D and achieve data-driven innovation in pharmaceuticals
- Apr 05, 2022: AMR Action Fund launches investments to promote innovation to overcome AMR
- Mar 16, 2022: Shionogi announces the results of comprehensive maternal and child health support activities undertaken in Kenya under the “Mother to Mother SHIONOGI Project” - Health of Maasai Mothers and Children has Improved -
- Methodology
- Ratio Definitions
- About the Publisher
- Contact the Publisher
- Disclaimer
- Shionogi & Co Ltd, Key Facts
- Shionogi & Co Ltd, Key Employees
- Shionogi & Co Ltd, Key Employee Biographies
- Shionogi & Co Ltd, Major Products and Services
- Shionogi & Co Ltd, History
- Shionogi & Co Ltd, Other Locations
- Shionogi & Co Ltd, Subsidiaries
- Shionogi & Co Ltd, Joint Venture
- Shionogi & Co Ltd, Key Competitors
- Shionogi & Co Ltd, Ratios based on current share price
- Shionogi & Co Ltd, Annual Ratios
- Shionogi & Co Ltd, Interim Ratios
- Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
- Shionogi & Co Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- Shionogi & Co Ltd, Performance Chart (2018 - 2022)
- Shionogi & Co Ltd, Ratio Charts
- Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022
Samples
LOADING...
Companies Mentioned
A selection of companies mentioned in this report includes:
- Wakamoto Pharmaceutical Co Ltd
- Takeda Pharmaceutical Co Ltd
- Santen Pharmaceutical Co Ltd
- Otsuka Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Chugai Pharmaceutical Co Ltd
- Wakamoto Pharmaceutical Co Ltd
- Otsuka Pharmaceutical Co Ltd
- Takeda Pharmaceutical Co Ltd
- Santen Pharmaceutical Co Ltd
- Chugai Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd